Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSTEM Inj. in Moderate to Severe Subacute and Chronic Atopic Dermatitis
NCT04137562Phase 2Active, not recruiting
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Dec 2019
- Primary completion
- Jan 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in atopic dermatitis (AD) comparing ADSTEM Inj with Placebo (2 arms). Primary endpoint: Eczema Area and Severity Index 50% reduction at 16 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
ADSTEM
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04137562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137562.